Dr. John Charlson, MD
Claim this profileMedical College of Wisconsin
Studies Cancer
Studies Soft Tissue Sarcoma
15 reported clinical trials
24 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
FOXO1 fusion negative
2Soft Tissue Sarcoma
Stage IV
Stage III
p16 positive
Affiliated Hospitals
Clinical Trials John Charlson, MD is currently running
ADI-PEG 20 + Chemotherapy
for Leiomyosarcoma
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Recruiting1 award Phase 310 criteria
Immunotherapy + Chemotherapy
for Sarcoma
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting2 awards Phase 310 criteria
More about John Charlson, MD
Clinical Trial Related5 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments John Charlson, MD has experience with
- Temozolomide
- Nivolumab
- Cyclophosphamide
- Pembrolizumab
- Abemaciclib
- Cabozantinib
Breakdown of trials John Charlson, MD has run
Cancer
Soft Tissue Sarcoma
Uterine Leiomyosarcoma
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John Charlson, MD specialize in?
John Charlson, MD focuses on Cancer and Soft Tissue Sarcoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is John Charlson, MD currently recruiting for clinical trials?
Yes, John Charlson, MD is currently recruiting for 4 clinical trials in Milwaukee Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that John Charlson, MD has studied deeply?
Yes, John Charlson, MD has studied treatments such as Temozolomide, Nivolumab, Cyclophosphamide.
What is the best way to schedule an appointment with John Charlson, MD?
Apply for one of the trials that John Charlson, MD is conducting.
What is the office address of John Charlson, MD?
The office of John Charlson, MD is located at: Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States. This is the address for their practice at the Medical College of Wisconsin.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.